Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,164Revenue $M7,670Net Margin (%)30.4Altman Z-Score7.3
Enterprise Value $M91,657EPS $2.4Operating Margin %37.6Piotroski F-Score8
P/E(ttm)39.7Beneish M-Score-2.5Pre-tax Margin (%)35.2Higher ROA y-yY
Price/Book13.610-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales12.05-y EBITDA Growth Rate %23.1Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow33.5y-y EBITDA Growth Rate %71.3ROA % (ttm)15.3Higher Current Ratio y-yY
Dividend Yield %--PEG1.7ROE % (ttm)43.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M793ROIC % (ttm)46.7Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGRonald Muhlenkamp 2015-03-31 Reduce-0.02%$110.51 - $128.5
($119.49)
$ 116.20-3%Reduce 0.81%85,540
CELGJoel Greenblatt 2015-03-31 Add0.01%$110.51 - $128.5
($119.49)
$ 116.20-3%Add 75.33%17,987
CELGMario Gabelli 2015-03-31 Reduce$110.51 - $128.5
($119.49)
$ 116.20-3%Reduce 0.08%24,940
CELGKen Fisher 2015-03-31 Add$110.51 - $128.5
($119.49)
$ 116.20-3%Add 1.14%229,918
CELGRonald Muhlenkamp 2014-12-31 Reduce-1.03%$86.38 - $118.68
($105.53)
$ 116.2010%Reduce 41.31%86,240
CELGJoel Greenblatt 2014-12-31 Buy 0.01%$86.38 - $118.68
($105.73)
$ 116.2010%New holding10,259
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 116.2029%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 116.2029%Sold Out0
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 116.2029%Add 77.12%232,137
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 116.2053%Reduce 51.74%144,140
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 116.2053%New holding688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 116.2053%New holding63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 116.2053%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-03-31 Add0.05%$69.645 - $85.97
($79.19)
$ 116.2047%Add 1.29%298,650
CELGKen Fisher 2014-03-31 Add0.01%$69.645 - $85.97
($79.19)
$ 116.2047%Add 1591.80%74,642
CELGMario Gabelli 2014-03-31 Reduce$69.645 - $85.97
($79.19)
$ 116.2047%Reduce 3.58%21,540
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.19)
$ 116.2047%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.245 - $85.385
($79.13)
$ 116.2047%Add 2.87%294,850
CELGMario Gabelli 2013-12-31 Add$72.245 - $85.385
($79.13)
$ 116.2047%Add 6.69%22,340
CELGKen Fisher 2013-12-31 Reduce$72.245 - $85.385
($79.13)
$ 116.2047%Reduce 11.41%4,412
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2015-02-26Sell15,000$122.89-8.02view
CASEY MICHAEL DDirector 2015-02-25Sell15,000$123.19-8.24view
KARSEN PERRY Asee remarks 2015-02-11Sell27,896$120.12-5.89view
Alles Mark JSee Remarks 2015-02-06Sell117,099$120.68-6.33view
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.01-5.81view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.47-0.38view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.06-1.76view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.2-4.37view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.272.51view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.235.42view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 

More From Other Websites
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO... May 13 2015
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO... May 13 2015
This biotech stock is a bargain: Strategist May 13 2015
Gilead: No Big Deals May 13 2015
Short Sellers Start to Get Nervous on Biotech May 12 2015
Stevens Capital’s Top New Stock Picks Include Celgene Corporation (CELG), Chipotle Mexican Grill,... May 11 2015
Celgene CEO Says Early-Stage Partnerships Begin to Show Promise May 08 2015
EU patent office revokes Celgene Revlimid patent; appeal planned May 07 2015
Celgene: So Much For That Patent Hearing May 07 2015
Agios (AGIO) Reports Narrower-than-Expected Loss in Q1 - Tale of the Tape May 07 2015
CELGENE CORP /DE/ Financials May 06 2015
The Zacks Analyst Blog Highlights: Celgene, Laboratory Corp. of America Holdings, Quest Diagnostics... May 06 2015
Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology May 06 2015
Will Agios (AGIO) Disappoint this Earnings Season? - Analyst Blog May 05 2015
Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. May 05 2015
Corporate Earnings, FOMC Drive Financial Markets in May 1 Week May 05 2015
Beyond Pharma: 3 Healthcare Choices - Analyst Blog May 05 2015
How AstraZeneca plc’s “Externalisation” Deals Are Set To Boost Growth May 05 2015
The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years May 05 2015
Global cancer drug spending hits $100 billion in 2014 - IMS Health May 05 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK